Related Experiment Video
Updated: Apr 25, 2026

Systemic Delivery of MicroRNA Using Recombinant Adeno-associated Virus Serotype 9 to Treat Neuromuscular Diseases in Rodents
Published on: August 10, 2018
Identifying a polymorphic 'switch' that influences miRNAs' regulation of a myasthenia gravis risk pathway
Lili Yang1, Jianjian Wang1, Xuesong Sun1
1Department of Neurology, The Second Affiliated Hospital, Harbin Medical University, Harbin, Heilongjiang Province, China.
Abstract:
The significant roles of genetic variants in myasthenia gravis (MG) pathogenesis have been demonstrated in many studies, and recently it has been revealed that aberrant level/regulation of microRNAs (miRNAs) might contribute to the initiation and progression of MG. However, the dysfunction of miRNA associated with single nucleotide polymorphisms (miRSNPs) has not been well investigated in MG. In this study, we created a contemporary catalog of 89 MG risk genes via manual literature-mining. Based on this risk gene catalog, we obtained 18 MG risk pathways. Furthermore, we identified 93 miRNAs that target MG risk pathways and revealed the miRSNPs 'switches' in miRNA regulation in the MG risk pathways by integrating the database information of miRSNPs. We also constructed a miRNA-mediated SNP switching pathway network (MSSPN) to intuitively analyze miRNA regulation of MG risk pathways and the relationship of the polymorphism 'switch' with these changes in regulation. Moreover, we carried out in-depth dissection on the correlation between hsa05200 (pathway in cancer) and MG development, and elaborated the significance of 4 high-risk genes. By network analysis and literature mining, we proposed a potential mechanism of miRSNPs→gene→pathway effects on MG pathogenesis, especially for rs28457673 (miR-15/16/195/424/497 family)→IGF1R→hsa05200 (pathway in cancer). Therefore, our studies have revealed a functional role for genetic modulators in MG pathogenesis at a systemic level, which could be informative for further miRNA and miRSNPs studies in MG.
Insights
Genetic variants and microRNAs (miRNAs) influence myasthenia gravis (MG). This study identifies miRNA-associated single nucleotide polymorphisms (miRSNPs) impacting MG pathways, revealing a novel mechanism involving genetic modulators in disease pathogenesis.
Area of Science:
- Genetics
- Immunology
- Molecular Biology
Background:
- Genetic variants and microRNA (miRNA) dysregulation are implicated in myasthenia gravis (MG) pathogenesis.
- The role of miRNA-associated single nucleotide polymorphisms (miRSNPs) in MG remains underexplored.
Purpose of the Study:
- To investigate the functional role of miRSNPs in MG pathogenesis.
- To construct a network illustrating miRNA-mediated regulation of MG risk pathways and the impact of miRSNPs.
Main Methods:
- Manual literature mining to create a catalog of 89 MG risk genes.
- Identification of 18 MG risk pathways and 93 targeting miRNAs.
- Integration of miRSNP database information to reveal regulatory 'switches' and construction of a miRNA-mediated SNP switching pathway network (MSSPN).
Main Results:
- Identified 93 miRNAs targeting 18 MG risk pathways.
- Revealed miRSNP 'switches' influencing miRNA regulation within these pathways.
- Proposed a potential mechanism (miRSNPs→gene→pathway) for MG pathogenesis, exemplified by rs28457673 impacting the cancer pathway (hsa05200) via IGF1R.
Conclusions:
- Genetic modulators, specifically miRSNPs, play a functional role in MG pathogenesis at a systemic level.
- The study provides a framework for understanding miRNA and miRSNP involvement in MG.
- Findings highlight potential therapeutic targets and diagnostic markers for MG.
Related Concept Videos
Myasthenia Gravis ll: Pathophysiology
Myasthenia Gravis: Overview and Treatment
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which...
MicroRNAs
MicroRNAs
MicroRNAs
Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

